|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's Range||61.76 - 62.27|
|52 Week Range||54.84 - 79.05|
|PE Ratio (TTM)||22.56|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||66.87|
BRUSSELS, June 13, 2017 /PRNewswire/ -- UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta from pregnant women to their infants. The study used a sensitive immunoassay designed specifically to measure CIMZIA and found no measurable levels in 13 out of 14 infant blood samples at birth, and in all infant samples at weeks four and eight after birth.
Its partner and its rival have a lot riding on the fate of Evenity.
THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical fractures (primary endpoints) and non-vertebral fractures (key secondary endpoint) in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone.